IMMUNITYBIO, INC. Operating Income
IMMUNITYBIO, INC. (IBRX) reported Operating Income of -$61.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- IMMUNITYBIO, INC. operating income (loss) for the quarter ending 2026-06-30 was -$61.70M.
- IMMUNITYBIO, INC. operating income (loss) for the quarter ending 2026-03-31 was -$69.79M.
- IMMUNITYBIO, INC. operating income (loss) for the quarter ending 2025-12-31 was -$64.68M.
- IMMUNITYBIO, INC. operating income (loss) for the quarter ending 2025-09-30 was -$55.63M.
- IMMUNITYBIO, INC. operating income (loss) for fiscal 2025 was -$256.03M.
- IMMUNITYBIO, INC. operating income (loss) for fiscal 2024 was -$344.18M.
- IMMUNITYBIO, INC. operating income (loss) for fiscal 2023 was -$362.25M.
- IMMUNITYBIO, INC. operating income (loss) for fiscal 2022 was -$351.30M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$61.70M 10-Q · filed 2026-08-04 | -$131.49M 10-Q · filed 2026-08-04 | -$196.17M derived: sum of 3 quarters · filed 2026-08-04 | -$251.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$69.79M 10-Q · filed 2026-05-07 | -$134.47M derived: sum of 2 quarters · filed 2026-05-07 | -$190.10M derived: sum of 3 quarters · filed 2026-05-07 | -$261.39M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$64.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$120.31M derived: sum of 2 quarters · filed 2026-02-23 | -$191.60M derived: sum of 3 quarters · filed 2026-08-04 | -$256.03M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$55.63M 10-Q · filed 2025-11-05 | -$126.92M derived: sum of 2 quarters · filed 2026-08-04 | -$191.34M 10-Q · filed 2025-11-05 | -$260.74M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$71.28M 10-Q · filed 2026-08-04 | -$135.71M 10-Q · filed 2026-08-04 | -$205.11M derived: sum of 3 quarters · filed 2026-08-04 | -$285.37M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$64.43M 10-Q · filed 2026-05-07 | -$133.83M derived: sum of 2 quarters · filed 2026-05-07 | -$214.08M derived: sum of 3 quarters · filed 2026-05-07 | -$313.42M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$69.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$149.65M derived: sum of 2 quarters · filed 2026-02-23 | -$248.99M derived: sum of 3 quarters · filed 2026-02-23 | -$344.18M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | -$80.25M 10-Q · filed 2025-11-05 | -$179.59M derived: sum of 2 quarters · filed 2025-11-05 | -$274.78M 10-Q · filed 2025-11-05 | -$360.17M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | -$99.33M 10-Q · filed 2025-08-05 | -$194.53M 10-Q · filed 2025-08-05 | -$279.92M derived: sum of 3 quarters · filed 2026-02-23 | -$360.05M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | -$95.20M 10-Q · filed 2025-05-12 | -$180.59M derived: sum of 2 quarters · filed 2026-02-23 | -$260.72M derived: sum of 3 quarters · filed 2026-02-23 | -$345.87M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | -$85.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$165.53M derived: sum of 2 quarters · filed 2026-02-23 | -$250.67M derived: sum of 3 quarters · filed 2026-02-23 | -$362.25M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | -$80.14M 10-Q · filed 2024-11-12 | -$165.28M derived: sum of 2 quarters · filed 2024-11-12 | -$276.86M 10-Q · filed 2024-11-12 | -$361.76M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | -$85.14M 10-Q · filed 2024-08-12 | -$196.72M 10-Q · filed 2024-08-12 | -$281.63M derived: sum of 3 quarters · filed 2025-03-03 | -$372.43M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | -$111.58M 10-Q · filed 2024-05-09 | -$196.48M derived: sum of 2 quarters · filed 2025-03-03 | -$287.28M derived: sum of 3 quarters · filed 2025-03-03 | -$366.91M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | -$84.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$175.70M derived: sum of 2 quarters · filed 2025-03-03 | -$255.33M derived: sum of 3 quarters · filed 2025-03-03 | -$351.30M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | -$90.80M 10-Q · filed 2023-11-09 | -$170.43M derived: sum of 2 quarters · filed 2023-11-09 | -$266.40M 10-Q · filed 2023-11-09 | -$345.67M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | -$79.62M 10-Q · filed 2023-08-08 | -$175.59M 10-Q · filed 2023-08-08 | -$254.87M derived: sum of 3 quarters · filed 2024-03-19 | -$333.70M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | -$95.97M 10-Q · filed 2023-05-11 | -$175.25M derived: sum of 2 quarters · filed 2024-03-19 | -$254.08M derived: sum of 3 quarters · filed 2024-03-19 | -$339.99M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | -$79.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$158.11M derived: sum of 2 quarters · filed 2024-03-19 | -$244.02M derived: sum of 3 quarters · filed 2024-03-19 | -$330.28M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | -$78.84M 10-Q · filed 2022-11-09 | -$164.74M derived: sum of 2 quarters · filed 2022-11-09 | -$251.01M 10-Q · filed 2022-11-09 | -$281.89M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-06-30 | -$85.91M 10-Q · filed 2022-08-08 | -$172.17M 10-Q · filed 2022-08-08 | -$203.06M derived: sum of 3 quarters · filed 2024-03-19 | -$268.93M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-03-31 | -$86.26M 10-K · filed 2024-03-19 | -$117.15M derived: sum of 2 quarters · filed 2024-03-19 | -$183.03M derived: sum of 3 quarters · filed 2024-03-19 | -$233.94M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2020-12-31 | -$30.89M 10-K · filed 2021-03-04 | -$96.76M derived: sum of 2 quarters · filed 2021-11-12 | -$147.68M derived: sum of 3 quarters · filed 2021-11-12 | -$220.88M 10-K · filed 2023-03-01 | -$91.63M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | -$65.88M 10-Q · filed 2021-11-12 | -$21.93M 10-Q · filed 2020-11-09 | -$116.79M derived: sum of 2 quarters · filed 2021-11-12 | -$153.50M 10-Q · filed 2021-11-12 | -$60.74M 10-Q · filed 2020-11-09 | -$169.61M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | -$50.92M 10-Q · filed 2021-08-12 | -$20.23M 10-Q · filed 2020-08-07 | -$87.62M 10-Q · filed 2021-08-12 | -$38.81M 10-Q · filed 2020-08-07 | -$103.73M derived: sum of 3 quarters · filed 2021-08-12 | -$119.79M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | -$36.70M 10-Q · filed 2021-05-14 | -$18.59M 10-Q · filed 2020-05-11 | -$52.81M derived: sum of 2 quarters · filed 2021-05-14 | -$68.88M derived: sum of 3 quarters · filed 2021-05-14 | -$86.17M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | -$16.11M 10-K · filed 2021-03-04 | -$32.18M derived: sum of 2 quarters · filed 2021-03-04 | -$49.47M derived: sum of 3 quarters · filed 2021-03-04 | -$156.25M 10-K · filed 2022-03-01 | -$67.81M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | -$16.07M 10-K · filed 2021-03-04 | -$33.36M derived: sum of 2 quarters · filed 2021-03-04 | -$51.70M 10-Q · filed 2020-11-09 | -$69.42M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | -$17.30M 10-K · filed 2021-03-04 | -$35.63M 10-Q · filed 2020-08-07 | -$53.35M derived: sum of 3 quarters · filed 2021-03-04 | -$77.46M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | -$18.34M 10-K · filed 2021-03-04 | -$36.05M derived: sum of 2 quarters · filed 2021-03-04 | -$60.16M derived: sum of 3 quarters · filed 2021-03-04 | -$88.44M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | -$17.72M 10-K · filed 2020-03-25 | -$41.83M derived: sum of 2 quarters · filed 2020-03-25 | -$70.11M derived: sum of 3 quarters · filed 2020-03-25 | -$98.39M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | -$24.11M 10-K · filed 2020-03-25 | -$52.39M derived: sum of 2 quarters · filed 2020-03-25 | -$80.67M 10-Q · filed 2019-11-05 | -$106.06M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-06-30 | -$28.28M 10-K · filed 2020-03-25 | -$56.56M 10-Q · filed 2019-08-06 | -$81.96M derived: sum of 3 quarters · filed 2020-03-25 | -$106.40M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-03-31 | -$28.28M 10-K · filed 2020-03-25 | -$53.68M derived: sum of 2 quarters · filed 2020-03-25 | -$78.12M derived: sum of 3 quarters · filed 2020-03-25 | -$101.94M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2017-12-31 | -$25.39M 10-K · filed 2019-03-13 | -$49.84M derived: sum of 2 quarters · filed 2019-03-13 | -$73.66M derived: sum of 3 quarters · filed 2019-03-13 | -$99.12M 10-K · filed 2020-03-25 | ||||
| 2017-09-30 | -$24.44M 10-K · filed 2019-03-13 | -$48.26M derived: sum of 2 quarters · filed 2019-03-13 | -$73.73M 10-Q · filed 2018-11-07 | -$98.87M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-06-30 | -$23.82M 10-K · filed 2019-03-13 | -$49.28M 10-Q · filed 2018-08-06 | -$74.43M derived: sum of 3 quarters · filed 2019-03-13 | -$107.20M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-03-31 | -$25.46M 10-K · filed 2019-03-13 | -$50.61M derived: sum of 2 quarters · filed 2019-03-13 | -$83.38M derived: sum of 3 quarters · filed 2019-03-13 | -$118.35M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2016-12-31 | -$25.14M 10-K · filed 2018-03-12 | -$57.92M derived: sum of 2 quarters · filed 2018-03-12 | -$92.88M derived: sum of 3 quarters · filed 2018-03-12 | -$124.50M 10-K · filed 2019-03-13 | ||||
| 2016-09-30 | -$32.77M 10-K · filed 2018-03-12 | -$67.74M derived: sum of 2 quarters · filed 2018-03-12 | -$99.36M 10-Q · filed 2017-11-07 | -$129.28M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | -$34.97M 10-K · filed 2018-03-12 | -$66.58M 10-Q · filed 2017-08-07 | -$96.50M derived: sum of 3 quarters · filed 2018-03-12 | -$142.96M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | -$31.62M 10-K · filed 2018-03-12 | -$31.59M 10-Q · filed 2016-05-16 | -$61.54M derived: sum of 2 quarters · filed 2018-03-12 | -$108.00M derived: sum of 3 quarters · filed 2018-03-12 | -$238.39M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2015-12-31 | -$29.92M 10-K · filed 2017-03-15 | -$76.38M derived: sum of 2 quarters · filed 2017-03-15 | -$206.78M derived: sum of 3 quarters · filed 2017-03-15 | -$238.88M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | -$46.46M 10-K · filed 2017-03-15 | -$42.79M 10-Q · filed 2015-11-12 | -$176.85M derived: sum of 2 quarters · filed 2017-03-15 | -$208.95M 10-Q · filed 2016-11-10 | -$158.95M 10-Q · filed 2015-11-12 | -$211.59M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-06-30 | -$130.40M 10-K · filed 2017-03-15 | -$84.08M 10-Q · filed 2015-09-10 | -$162.50M 10-Q · filed 2016-08-15 | -$116.16M 10-Q · filed 2015-09-10 | -$165.13M derived: sum of 3 quarters · filed 2017-03-15 | -$166.05M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-03-31 | -$32.10M 10-K · filed 2017-03-15 | -$34.73M derived: sum of 2 quarters · filed 2017-03-15 | -$35.65M derived: sum of 3 quarters · filed 2017-03-15 | -$36.85M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | -$2.63M 10-K · filed 2016-03-30 | -$3.55M derived: sum of 2 quarters · filed 2016-03-30 | -$4.75M derived: sum of 3 quarters · filed 2016-03-30 | -$5.58M 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | -$919.00K 10-K · filed 2016-03-30 | -$897.00K 10-Q · filed 2015-11-12 | -$2.12M derived: sum of 2 quarters · filed 2016-03-30 | -$2.96M 10-Q · filed 2015-11-12 | ||||
| 2014-06-30 | -$1.20M 10-K · filed 2016-03-30 | -$1.17M 10-Q · filed 2015-09-10 | -$2.07M 10-Q · filed 2015-09-10 | |||||
| 2014-03-31 | -$826.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |